Equities Analysts Set Expectations for SABS Q3 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities researchers at Brookline Capital Markets issued their Q3 2026 earnings estimates for shares of SAB Biotherapeutics in a report issued on Friday, May 15th. Brookline Capital Markets analyst K. Raja forecasts that the company will earn ($0.25) per share for the quarter. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.22) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.17) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at $1.17 EPS.

A number of other research firms have also issued reports on SABS. HC Wainwright increased their target price on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Chardan Capital increased their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Rodman & Renshaw reiterated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Finally, Wall Street Zen downgraded shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $3.55 on Wednesday. The firm has a market cap of $180.87 million, a PE ratio of -1.68 and a beta of 0.55. SAB Biotherapeutics has a 52-week low of $1.60 and a 52-week high of $6.60. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $3.85 and its two-hundred day moving average is $3.84.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SABS. Vivo Capital LLC purchased a new stake in SAB Biotherapeutics in the third quarter valued at approximately $22,954,000. Commodore Capital LP purchased a new stake in SAB Biotherapeutics in the third quarter valued at approximately $8,847,000. RA Capital Management L.P. purchased a new stake in SAB Biotherapeutics in the third quarter valued at approximately $8,847,000. Woodline Partners LP purchased a new stake in SAB Biotherapeutics in the third quarter valued at approximately $5,730,000. Finally, Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $8,222,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.